Credit Suisse Group reiterated their neutral rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note released on Wednesday morning, Briefing.com Automated Import reports.

TEVA has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Guaranty Federal Bancshares from a hold rating to a sell rating in a research note on Tuesday, April 23rd. Sanford C. Bernstein set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, June 18th. Bank of America set a $165.00 target price on shares of PVH and gave the stock a buy rating in a research note on Thursday, May 30th. Royal Bank of Canada set a $60.00 target price on shares of Masonite International and gave the stock a buy rating in a research note on Friday, May 3rd. Finally, Maxim Group reissued a hold rating on shares of Arlington Asset Investment in a research note on Thursday, May 2nd. Five research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of Hold and a consensus target price of $15.83.

Shares of TEVA stock traded down $0.21 during trading hours on Wednesday, hitting $8.97. 17,292,732 shares of the company’s stock traded hands, compared to its average volume of 13,789,160. The firm has a 50 day moving average price of $9.17. The stock has a market cap of $9.30 billion, a PE ratio of 3.20, a PEG ratio of 1.13 and a beta of 1.62. Teva Pharmaceutical Industries has a 12 month low of $7.96 and a 12 month high of $25.96. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.02. The firm had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The company’s revenue for the quarter was down 15.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.94 earnings per share. Equities analysts forecast that Teva Pharmaceutical Industries will post 2.27 earnings per share for the current fiscal year.

In other news, Director Sol J. Barer purchased 111,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average cost of $8.98 per share, for a total transaction of $996,780.00. Following the completion of the acquisition, the director now owns 115,942 shares in the company, valued at $1,041,159.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the transaction, the vice president now owns 49,659 shares in the company, valued at $567,105.78. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in TEVA. Cutler Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $2,539,000. Prudential Financial Inc. increased its stake in Teva Pharmaceutical Industries by 105.5% during the fourth quarter. Prudential Financial Inc. now owns 218,134 shares of the company’s stock worth $3,364,000 after acquiring an additional 111,965 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Teva Pharmaceutical Industries by 3.5% during the fourth quarter. Bank of New York Mellon Corp now owns 1,975,038 shares of the company’s stock worth $30,454,000 after acquiring an additional 67,168 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Teva Pharmaceutical Industries by 2.0% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 76,187 shares of the company’s stock worth $1,175,000 after acquiring an additional 1,497 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Teva Pharmaceutical Industries by 2.7% during the fourth quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock worth $103,125,000 after acquiring an additional 175,173 shares during the last quarter. Institutional investors and hedge funds own 65.08% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: What is the Stochastic Momentum Index (SMI)?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.